RET
14 drugs Oncology
5
approved indications
14
Approved Drugs
13
Companies
32
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (13 companies)
✓ All 14 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (32 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Bayer 2 drugs
EISAI INC 1 drug
EXELIXIS INC 1 drug
By Therapeutic Area
Other 10 drugs
Oncology 4 drugs
Drugs by Company PRO
EISAI INC 1 drug
EXELIXIS INC 1 drug
Eli Lilly 1 drug
CPPI CV 1 drug
Viatris 1 drug
NATCO PHARMA 1 drug
BLUEPRINT MEDICINES 1 drug
Takeda 1 drug
EXELIXIS 1 drug
+ 3 more companies
By Therapeutic Area
Other 10 drugs
LENVIMA, CABOMETYX, SUTENT, STIVARGA +6 more
Oncology 4 drugs
RETEVMO, SORAFENIB TOSYLATE, SUNITINIB MALATE, ALECENSA
Indications Treated
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid CarcinomaLocally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancerAdvanced renal cell carcinoma (first-line, in combination with pembrolizumab)Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus)Unresectable hepatocellular carcinoma (first-line)Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)Medullary Thyroid CancerGastrointestinal Stromal TumorPancreatic Neuroendocrine TumorNon-Small Cell Lung CancerThyroid CancerSolid TumorsMetastatic RET fusion-positive non-small cell lung cancerAdvanced or metastatic RET fusion-positive thyroid cancerGastrointestinal stromal tumor (GIST)Advanced renal cell carcinoma (RCC)Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomyProgressive, well-differentiated pancreatic neuroendocrine tumors (pNET)Metastatic colorectal cancerLocally advanced, unresectable or metastatic gastrointestinal stromal tumorHepatocellular carcinomaAdvanced renal cell carcinomaHepatocellular carcinoma previously treated with sorafenibLocally advanced or metastatic differentiated thyroid cancerWell-differentiated pancreatic neuroendocrine tumorsWell-differentiated extra-pancreatic neuroendocrine tumorsUnresectable hepatocellular carcinomaLocally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment + 2 more
All Drugs Targeting RET
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LENVIMA | EISAI INC | 2015 | 5 | |
| CABOMETYX | EXELIXIS INC | 2016 | 5 | |
| RETEVMO | Eli Lilly | 2020 | 4 | Oncology |
| SUTENT | CPPI CV | 2006 | 4 | |
| SORAFENIB TOSYLATE | Viatris | 2020 | 3 | Oncology |
| SUNITINIB MALATE | NATCO PHARMA | 2021 | 3 | Oncology |
| STIVARGA | Bayer | 2012 | 3 | |
| NEXAVAR | Bayer | 2005 | 3 | |
| GAVRETO | BLUEPRINT MEDICINES | 2020 | 2 | |
| ICLUSIG | Takeda | 2012 | 2 | |
| COMETRIQ | EXELIXIS | 2012 | 1 | |
| RESNIBEN | AZURITY | - | 1 | |
| ALECENSA | Roche | 2015 | 1 | Oncology |
| CAPRELSA | Sanofi | 2011 | 1 |